⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24211093 | 1.00 | — | — | |
| SCHEMBL20329196 | 1.00 | — | — | |
| SCHEMBL20329197 | 0.91 | — | — | |
| SCHEMBL26474203 | 0.91 | — | — | |
| SCHEMBL26474211 | 0.85 | — | — | |
| SCHEMBL20329200 | 0.85 | — | — | |
| SCHEMBL21202663 | 0.84 | — | — | |
| SCHEMBL24778340 | 0.84 | — | — | |
| SCHEMBL15964498 | 0.84 | — | — | |
| SCHEMBL16904631 | 0.83 | FBP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |